Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study
Sponsor: Alex's Lemonade Stand Foundation
Listed as NCT06068075, this NA trial focuses on Ewing Sarcoma and Ewing Sarcoma of Bone and remains actively recruiting participants. Sponsored by Alex's Lemonade Stand Foundation, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
-
Feb 2025 — Feb 2026 [monthly]
Recruiting NA
-
Dec 2024 — Feb 2025 [monthly]
Recruiting NA
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Nov 2023 — Jul 2024 [monthly]
Recruiting NA
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alex's Lemonade Stand Foundation
- Conquer Cancer Foundation
- Dana-Farber Cancer Institute
- Harvard University
- Sam Day Foundation
For direct contact, visit the study record on ClinicalTrials.gov .